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AbsTrACT
Objective to investigate the underlying mechanisms 
behind changes in glucose homeostasis with delivery 
of propionate to the human colon by comprehensive 
and coordinated analysis of gut bacterial composition, 
plasma metabolome and immune responses.
Design twelve non-diabetic adults with overweight 
and obesity received 20 g/day of inulin-propionate 
ester (iPe), designed to selectively deliver propionate 
to the colon, a high-fermentable fibre control (inulin) 
and a low-fermentable fibre control (cellulose) in a 
randomised, double-blind, placebo-controlled, cross-
over design. Outcome measurements of metabolic 
responses, inflammatory markers and gut bacterial 
composition were analysed at the end of each 42-day 
supplementation period.
results Both iPe and inulin supplementation 
improved insulin resistance compared with cellulose 
supplementation, measured by homeostatic model 
assessment 2 (mean±SeM 1.23±0.17 iPe vs 
1.59±0.17 cellulose, p=0.001; 1.17±0.15 inulin vs 
1.59±0.17 cellulose, p=0.009), with no differences 
between iPe and inulin (p=0.272). Fasting insulin 
was only associated positively with plasma tyrosine 
and negatively with plasma glycine following inulin 
supplementation. iPe supplementation decreased 
proinflammatory interleukin-8 levels compared with 
cellulose, while inulin had no impact on the systemic 
inflammatory markers studied. inulin promoted changes 
in gut bacterial populations at the class level (increased 
actinobacteria and decreased clostridia) and order level 
(decreased clostridiales) compared with cellulose, with 
small differences at the species level observed between 
iPe and cellulose.
Conclusion these data demonstrate a distinctive 
physiological impact of raising colonic propionate 
delivery in humans, as improvements in insulin 
sensitivity promoted by iPe and inulin were 
accompanied with different effects on the plasma 
metabolome, gut bacterial populations and markers of 
systemic inflammation.
InTrODuCTIOn
In both epidemiological studies and randomised 
controlled trials, higher intakes of dietary fibre are 
associated with a reduced risk of type 2 diabetes.1 
An improvement in metabolic health risk factors is 
greatest when dietary fibre intake exceeds 25 g/day,1 
however, at the population level, average intakes are 
considerably below this amount.2 Understanding 
the mechanisms by which increased dietary fibre 
intake exerts health benefits may allow us to exploit 
them to prevent or treat metabolic disease.
Dietary fibre intake modulates the composition 
and activity of the gut microbiota.3 An improve-
ment in whole-body insulin sensitivity following 
increased dietary fibre intake has been linked to 
increased colonic production of the short-chain 
fatty acid (SCFA) acetate, propionate and butyrate, 
the major end products of dietary fibre fermenta-
tion by the gut bacteria.4 5 Evidence in human trials 
significance of this study
What is already known on this subject?
 ► Short-chain fatty acids (SCFA), derived from 
fermentation of dietary fibre by the gut 
microbiota, have been shown to improve host 
insulin sensitivity.
 ► We have previously shown that supplementing 
the diet with inulin-propionate ester (IPE), 
designed to deliver the SCFA propionate to 
the colon, improves glucose homeostasis in 
humans, but the underlying mechanisms are 
unclear.  on
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significance of this study
What are the new findings?
 ► Dietary supplementation with 20 g/day of IPE or the high-
fermentable control fibre inulin for 42 days improved insulin 
sensitivity compared with the low-fermentable fibre control 
cellulose in adults with overweight and obesity. There were 
no differences with IPE compared with inulin.
 ► Fasting insulin following each supplementation period 
was associated with different plasma metabolome 
profiles. A positive association between plasma N-acetyl 
glycoproteins and fasting insulin was observed following 
cellulose supplementation, which was not found after inulin 
or IPE supplementation. Tyrosine (positively) and glycine 
(negatively) were only associated with fasting insulin 
following inulin supplementation.
 ► The improvement in metabolic health with IPE relative to 
cellulose supplementation was accompanied with decreased 
proinflammatory interleukin-8 (IL-8) levels. Analysis in vitro 
found that peripheral blood mononuclear cells isolated from 
healthy humans secrete less IL-8 in media containing sodium 
propionate compared with both sodium acetate and sodium 
chloride.
 ► IPE supplementation caused changes in gut bacterial 
populations compared with cellulose only at the species level. 
Inulin supplementation changed gut bacterial composition 
at both the class and order level, relative to cellulose, and 
promoted a bifidogenic effect.
How might it impact on clinical practice in the foreseeable 
future?
 ► Strategies that promote colonic propionate production 
may represent a more targeted route to improve glucose 
homeostasis in individual patients, depending on the 
underlying mechanisms contributing to the metabolic 
disorder.
has shown that increasing dietary fibre intake protects against 
weight gain6 7 and improves markers of insulin sensitivity.8–10 
These positive effects have been observed with a number of 
dietary fibre supplements, including whole-grain diets,10 resis-
tant starches9 and inulin-type fructans,8 which produce varying 
amounts of SCFAs in the gut owing to the complex interaction 
between the physicochemical properties of the substrate and the 
gut microbiota.5 11
SCFAs have been suggested to improve insulin sensitivity via 
effects on metabolic pathways and receptor-mediated mecha-
nisms at various tissue and organ sites.12 Specifically, SCFAs act 
as ligands for G-protein-coupled receptors (GPR) free fatty acid 
receptor 2 (FFAR2), FFAR3 and GPR109a, which are expressed 
throughout the body and have been shown to modulate energy 
homeostasis.13 Our previous work has primarily focused on 
the role of the SCFA propionate, as a number of studies have 
shown that mice receiving a gut microbial transplant that 
promotes caecal propionate production have improved body 
composition and glycaemic control.14 15 We have described how 
inulin-propionate ester (IPE) can target delivery of propionate 
to the colon,16 17 and observed that long-term ingestion of 10 g/
day IPE ameliorates body weight gain and the development of 
abdominal visceral adipose tissue in overweight human adults.16 
A secondary outcome of this study was the observation that 
IPE improved glucose homeostasis, which was associated with 
a direct action of propionate on human islet β-cells.18 These 
studies indicated in vitro that FFAR2 is expressed in human 
islets and that propionate-mediated signalling potentiated 
glucose-stimulated insulin release and protected from apoptotic 
stimuli.18 Long-term colonic propionate delivery also reduced 
levels of non-esterified fatty acid (NEFA),18 a recognised factor 
that contributes to β-cell dysfunction and peripheral insulin 
resistance.19 The stimulation of FFAR2 expressed on adipocytes 
has previously been shown to inhibit adipocyte lipolysis and the 
levels of circulating NEFA.20
Insulin-resistant states that develop with increasing adiposity 
have been linked to the activation of inflammatory responses in 
different organ sites, including adipose tissue, liver and skeletal 
muscle, which increases secretion and systemic levels of proinflam-
matory cytokines.21 It is recognised that increased dietary fibre 
intake and SCFA production have a profound effect on inflam-
matory and immune function in the colon, largely through effects 
on the generation of regulatory T cells (Treg)22 23 and mucosal 
secretion of IgA.24 Previous work highlights that SCFAs can also 
influence inflammatory and immune responses beyond their site of 
production in peripheral tissues.24–26 Supplementing naïve T cell 
cultures with propionate enhanced Treg development and reduced 
the expansion of inflammatory Th17 cells.26 The improvements 
in glucose homeostasis we have previously observed following 
long-term colonic propionate delivery may be partly explained by 
a dampening of the low-grade systemic inflammation that accom-
panies obesity.
Although there is increasing evidence that gut bacteria play 
a role in insulin resistance, the mechanisms have not been fully 
elucidated. Our previous work explored the effect of increasing 
colonic propionate production on gut bacterial composition, 
using batch-culture fermentation models in vitro, and found that 
improvements in host metabolic health with IPE supplementation 
were not due to changes in the gut bacterial populations exam-
ined.16 However, batch-culture models lack the complexity of the 
human gut; 16S ribosomal RNA (rRNA) gene sequencing of stool 
samples would allow a more physiologically relevant and deeper 
interrogation of the impact of long-term colonic propionate 
delivery on gut bacterial composition and the association of these 
changes with improvements in host metabolism.
The primary aim of the present study was to elucidate the 
underlying mechanisms behind improvements in glucose homeo-
stasis following long-term delivery of propionate to the human 
colon. In our previous studies, inulin was used as a control to 
account for changes to the composition and metabolic activity 
of the gut microbiota that may derive from the inulin content 
of IPE.21 We have previously found that 10 g/day IPE improved 
glucose homeostasis compared with an inulin control,16 18 
however, inulin has itself been associated with improvements 
in metabolic responses when compared with a non-fermentable 
or low-fermentable control, particularly when supplemented 
in higher doses (>15 g/day).8 27 Consequently, the present 
randomised cross-over trial used 20 g/day of IPE and inulin 
to probe the common mechanisms underlying improvements 
in insulin sensitivity following dietary supplementation with 
a high-fermentable fibre and to differentiate them from those 
driven specifically from the selective delivery of propionate to 
the human colon with IPE.
MeTHODs
All participants provided informed written consent prior to the 
clinical trial, which was approved by the London Brent Research 
Ethics Committee (14/LO/0645). The study was carried out in 
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Table 1 Characteristics of participants at screening
Sex, n
  Male 3
  Female 9
Age (years) 60±1 (49–65)
Race or ethnicity (n)
  White 11
  Black 1
Weight (kg) 84.6±3.2 (68.6–113.1)
BMI (kg/m2) 29.8±0.9 (26.2–37.0)
HbA1c (mmol/mol) 35.5±1.0 (30–42)
Triglycerides (mmol/L) 1.0±0.1 (0.6–1.3)
Cholesterol (mmol/L) 5.2±0.3 (3.6–6.9)
LDL cholesterol (mmol/L) 3.2±0.2 (2.1–4.8)
HDL cholesterol (mmol/L) 1.5±0.1 (0.9–2.1)
Alanine Transaminase (IU/L) 22.0±2.6 (10–38)
Data are expressed as mean±SEM; ranges in parentheses.
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
accordance with the Declaration of Helsinki and is registered 
with the ISRCTN registry (ISRCTN71814178).
Men and women aged 18–65 years, with a body mass index 
of 25–40 kg/m2, were recruited. Detailed exclusion criteria 
are presented in the online supplementary material. The 
study was conducted using a randomised, double-blind, place-
bo-controlled, cross-over design (online supplementary figure 
1). Participants received 20 g/day of a low-fermentable fibre 
control (cellulose; microcrystalline cellulose [ACI Group, 
Slough, UK]), a high-fermentable fibre control (inulin [Beneo-
Orafti HP, Kreglinger Europe, Antwerpen, Belgium]) and IPE 
for 42 days each in a random order. The 20 g/day dose of IPE 
would have provided 14.6 g/day of inulin (and 5.4 g/day esteri-
fied propionate) to the diet.16 Cellulose was used as a negative 
control due to its low fermentability and consequent low SCFA 
production. The supplements were provided to volunteers in 
10 g ready-to-use sachets and they were instructed to mix the 
contents into their normal diet twice a day. There was a washout 
period of at least 28 days between supplementation periods. The 
mean±SEM washout period between supplementation periods 
1–2 and 2–3 was 44±6 and 44±9 days, respectively. All partici-
pants were instructed to maintain their usual dietary and physical 
activity habits during the study period and regular communica-
tion between participants and study investigators encouraged 
good compliance. Participants returned their used and unused 
sachets to facilitate the estimation of compliance rates.
At the end of each 42-day supplementation period, partici-
pants attended the National Institute of Health Research Impe-
rial Clinical Research Facility to determine outcome measures. 
The primary outcome was change in glucose homeostasis. The 
day prior to the study visits, participants were requested to 
refrain from strenuous exercise and alcohol and to consume a 
standard evening meal prior to fasting overnight for >10 hours.
Mixed meal test
A cannula was inserted into an antecubital vein and two fasting 
blood samples were collected >5 min apart. At 0 min, partici-
pants were served a standard liquid meal (Ensure Plus, Abbott, 
UK: 660 kcal; 88.9 g carbohydrate, 21.6 g fat, 27.5 g protein) 
that was ingested within 10 min. Postprandial blood samples 
were taken at 10, 20, 30, 45, 60, 90, 120 and 180 min and anal-
ysed for glucose, insulin, NEFA, active glucagon-like-peptide 1 
(GLP-1), total peptide YY (PYY) and SCFA levels. 1H NMR spec-
troscopy was performed on fasting plasma samples for metabo-
lite analysis. A detailed description of blood sample collection 
and analysis is presented in the online supplementary material.
Immune and inflammatory phenotyping
IgA, IgG, IgM and C-reactive protein were measured in fasting 
serum samples by the Department of Chemical Pathology, Impe-
rial College Healthcare National Health Service Trust. Inter-
leukin (IL)-6, IL-8, IL-10, IL-12, IL-17A and tumour necrosis 
factor alpha (TNF-α) were measured in fasting serum using 
the Cytometric Bead Array (BD Biosciences, UK), according 
to the manufacturer’s protocol. Lipopolysaccharide binding 
protein (LBP) was measured in fasting serum by ELISA (Hycult 
Biotechnology, The Netherlands), according to the manu-
facturer’s protocol. Whole blood (30 mL) was collected into 
heparin-coated tubes and peripheral blood mononuclear cells 
(PBMC) were isolated using Ficoll-Hypaque (Amersham Biosci-
ences, UK) and cryopreserved in 10% dimethyl sulfoxide/fetal 
calf serum. A detailed description of PBMC analysis is presented 
in the online supplementary material.
stool DnA extraction and 16s rrnA gene sequencing 
(metataxonomics)
A stool sample was collected from volunteers on the final day 
of each supplementation period. DNA was extracted from each 
stool sample using the PowerLyzer PowerSoil DNA Isolation Kit 
(Mo Bio, Carlsbad, CA, USA) following manufacturer’s instruc-
tions, with the modification that samples were beaten for 3 min 
at speed 8 in a Bullet Blender Storm (Chembio, St Albans, UK). 
A detailed description of stool sample collection and metataxo-
nomic analysis is presented in the online supplementary material.
Calculations and statistical analysis
A detailed description of statistical analysis is presented in 
the online supplementary methods. Data are presented as 
means±SEM and p<0.05 was considered significant.
resulTs
Of 14 volunteers enrolled and randomised into the study, data 
were analysed from the 12 volunteers who completed all three 
42-day supplementation periods. The characteristics of these 
volunteers at screening are presented in table 1. There was no 
evidence of carry-over effects in the main outcome measures 
across the three supplementation periods (online supplementary 
table 1; supplementary figure 2).
Stool concentrations of SCFAs were not different following 
the three supplementation periods (figure 1A), however, 
the molar percentage of propionate was significantly higher 
following IPE supplementation compared with cellulose 
(27.9±2.6 vs 21.0%±2.0%, p=0.019; figure 2B). There were 
no differences in the total or molar percentages of SCFAs in 
fasting or postprandial blood between supplementation periods 
(figure 1C,D; online supplementary table 2).
Both inulin and IPE supplementation significantly improved 
measures of insulin sensitivity compared with cellulose 
supplementation, as assessed by homeostatic model assess-
ment 2 (1.17±0.15 inulin vs 1.59±0.17 cellulose, p=0.009; 
1.23±0.17 IPE vs 1.59±0.17 cellulose, p=0.001; figure 2A) 
and the Matsuda Insulin Sensitivity Index (4.0±0.7 inulin vs 
3.2±0.5 cellulose, p=0.014; 4.0±0.6 IPE vs 3.2±0.6 cellu-
lose, p=0.002; figure 2B). Inulin (6.3±1.5 vs 8.3±1.3 mmol/
L×µU/mL, p=0.042) and IPE supplementation (6.5±1.0 vs 
8.3±1.3 mmol/L×µU/mL, p=0.042) also significantly improved 
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Figure 1 The total and molar percentages of acetate, propionate and butyrate measured in stool (A, B) and fasting serum (C, D) following 42 
days of cellulose, inulin and inulin-propionate ester (IPE) supplementation. Mean±SEM (n=12). *P<0.05. Data were analysed by repeated measures 
analysis of variance (ANOVA) with post hoc Fisher's least significant difference (LSD) tests. SCFA, short-chain fatty acid. 
adipose tissue insulin resistance compared with cellulose supple-
mentation (figure 2C). The improvements in glucose homeo-
stasis observed following inulin and IPE supplementation were 
not associated with differences in body weight, compliance, 
self-reported food intake, physical activity or GI side effects 
compared with cellulose supplementation (online supplemen-
tary tables 3 and 4).
The improvement in indices of insulin sensitivity following 
inulin and IPE supplementation was driven by a significant 
reduction in fasting insulin values compared with cellulose 
supplementation (9.0±1.2 inulin vs 12.3±1.4 µU/mL cellulose, 
p=0.004; 9.4±1.2 IPE vs 12.3±1.4 µU/mL cellulose, p=0.004; 
figure 2D). There were no differences in the fasting or postpran-
dial values of other individual hormones or metabolites measured 
following the three supplementation periods (online supplemen-
tary table 5, supplementary figure 3). 1H NMR spectroscopy 
was performed on fasting plasma samples and the data set from 
the cellulose, inulin and IPE trials was modelled where fasting 
insulin values were used as Y to build an individual model per 
trial (table 2). This analysis identified common metabolites that 
were positively (valine and arginine) and negatively (high-den-
sity lipoproteins and unsaturated lipids) associated with fasting 
insulin following all three supplementation periods. Glutamine 
was negatively associated with fasting insulin following both 
inulin and IPE supplementation, but not cellulose, while tyro-
sine (positively) and glycine (negatively) were only associated 
with fasting insulin following inulin supplementation. N-acetyl 
glycoproteins were only positively associated with fasting insulin 
following cellulose supplementation.
PBMCs obtained from participants following the three supple-
mentation periods were stained with an immune-phenotyping 
antibody panel (online supplementary table 6) for multipa-
rameter flow cytometry to investigate potential modulation of 
lymphocyte subsets (figure 3A–F). The mean proportion of Treg 
among CD4+ T cells in the periphery was increased with inulin 
and IPE supplementation compared with cellulose, although this 
did not reach significance (p=0.104; figure 3A). In addition, 
there were no differences in the proportion of peripheral Th17 
cells (p=0.179; figure 3B), the ratio of Treg:Th17 cells (p=0.758; 
figure 3C) or proportion of CD19+ B cells (figure 3D, p=0.920) 
between supplementation periods. Given interest in the poten-
tial of SCFA supplementation to modulate T cell function, we 
also examined T cell effector recall responses to antigens using 
the cytomegalovirus/Epstein-Barr virus/flu (CEF) viral peptide 
pool and a recombinant Pseudomonas antigen, OprF. There 
were no differences in T cell response to CEF or OprF stimula-
tion between supplementation periods (figure 3E,F).
Differences in inflammatory and immune markers following 
the three supplementation periods are presented in online 
supplementary table 7. IL-17 and TNF-α are not shown, as only 
three volunteers had detectable values for these analytes. IPE 
supplementation significantly increased IgG levels compared 
with cellulose supplementation (10.29±0.45 vs 9.89±0.38 g/L, 
p=0.002; figure 4A). In addition, IPE supplementation signifi-
cantly decreased IL-8 levels (figure 4B) compared with cellulose 
supplementation (5.86±0.59 vs 8.69±1.74 pg/mL, p=0.041), 
with a trend observed for a difference between IPE and inulin 
supplementation values (5.86±0.59 vs 8.05±1.36 pg/mL; 
p=0.050). Analysis in vitro (figure 4C) observed that healthy 
human PBMCs cultured with sodium propionate secrete signifi-
cantly less IL-8 compared with both sodium chloride (p=0.021) 
and sodium acetate (p=0.040).
Both IPE and inulin supplementation periods decreased the 
diversity of bacterial species compared with cellulose (online 
supplementary figure 4A–C). The decrease in bacterial diversity 
observed with both inulin and IPE was not related to differences 
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Figure 2 (A) Homeostatic model assessment 2-insulin resistance (HOMA2-IR), (B) Matsuda Insulin Sensitivity Index (ISI), (C) adipose tissue insulin 
resistance (AT-IR) and (D) fasting insulin following 42 days of cellulose, inulin and inulin-propionate ester (IPE) supplementation. Each individual 
symbol represents a volunteer and lines represent mean±SEM (n=12). *P<0.05; **P<0.01. (A) and (D) were analysed by repeated measures analysis 
of variance (ANOVA) with post hoc Fisher's least significant difference (LSD) tests. (B) and (C) were analysed by Friedman test and post hoc Wilcoxon 
signed-rank test.
in richness, while there was a decreased enrichment (changes 
in evenness) with inulin compared with cellulose supplementa-
tion. We found no differences between supplementation periods 
on gut bacterial populations at the phylum level. At the class 
level, we observed an increase in Actinobacteria and decrease in 
Clostridia with inulin supplementation compared with cellulose 
(online supplementary figure 5A), while at the order level we 
found a decrease in the proportion of Clostridiales with inulin 
supplementation compared with cellulose (online supplementary 
figure 5B). At the species level, we found that the supplementa-
tion with inulin resulted in a higher proportion of Anaerostipes 
hadrus, Bifidobacterium faecale and Bacteroides caccae and a 
lower proportion of Blautia obeum, Blautia luti, Oscillibacter 
spp, Blautia faecis and Ruminococcus faecis, compared with 
cellulose (online supplementary figure 6). IPE supplementation 
resulted in a higher proportion of Bacteroides uniformis and 
Bacteroides xylanisolvens and a lower proportion of B. obeum 
and Eubacterium ruminantium compared with cellulose (online 
supplementary figure 7). We also found that the IPE supple-
mentation resulted in a higher proportion of Fusicatenibacter 
saccharivorans and a lower proportion of A. hadrus, B. faecale 
and Prevotella copri compared with the inulin supplementation 
period (online supplementary figure 8).
DIsCussIOn
The aim of the present study was to explore the mechanisms 
behind changes in insulin sensitivity observed when selectively 
increasing propionate delivery to the human colon compared with 
a high-fermentable fibre. We hypothesised that supplementing 
the diet of adults with overweight and obesity with 20 g IPE 
for 42 days would improve insulin sensitivity compared with 
both a high-fermentable (inulin) and low-fermentable (cellu-
lose) fibre control through modulatory effects on gut bacterial 
composition, reductions in NEFA levels and improvements in 
inflammatory markers. In our previous work, we observed that 
dietary supplementation with 10 g/day IPE improved glucose 
homeostasis compared with an inulin control.16 18 In the present 
study, we found that dietary supplementation with 20 g/day IPE 
promoted no superior impacts on measures of glucose homeo-
stasis compared with inulin, yet both IPE and inulin improved 
insulin resistance relative to cellulose.
The improvements in insulin sensitivity observed with IPE 
or inulin appear to encompass separate effects on gut bacterial 
communities and markers of systemic inflammation. Further-
more, we modelled fasting insulin responses with plasma 
metabolome profiles and observed that different metabolites 
were associated with fasting insulin after each supplemen-
tation period. We observed a positive association between 
plasma N-acetyl glycoproteins and fasting insulin after cellulose 
supplementation, which was not found following inulin or IPE 
supplementation. N-acetyl glycoproteins have previously been 
linked with increased insulin resistance28 and elevated risk of 
type 2 diabetes.29 Following both inulin and IPE supplementa-
tion, fasting insulin was negatively associated with glutamine. 
Previous studies have observed a similar inverse relationship 
between glutamine and insulin resistance.30 Tyrosine and glycine 
have also been identified as biomarkers of glucose homeo-
stasis31 32 and we found that fasting insulin was only associated 
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Table 2 Metabolites observed in fasting plasma that were 
significantly associated with fasting insulin following 42 days of 
cellulose, inulin and inulin-propionate ester (IPE) supplementation
Trial r2Y* Q2Y† Metabolite Association‡
Cellulose 0.94 0.31 Valine ↑
U1§ ↑
Arginine ↑
NAC1 ↑
NAC2 ↑
HDL ↓
Unsaturated lipids 
(mainly HDL)
↓
Phosphocholine lipids ↓
Inulin 0.98 0.2 Valine ↑
U1§ ↑
Arginine ↑
Tyrosine ↑
HDL ↓
Glutamine ↓
Unsaturated lipids 
(mainly HDL)
↓
Glycine ↓
IPE 0.97 0.32 Valine ↑
U1§ ↑
Arginine ↑
HDL ↓
Glutamine ↓
Unsaturated lipids 
(mainly HDL)
↓
Phosphocholine lipids ↓
*†Validation parameters of the corresponding partial least squares regression 
models.
‡Sign of association: ↑Upregulation and ↓downregulation at higher values of 
fasting insulin.
§Unknown metabolite.
HDL, high-density lipoprotein; NAC, N-acetyl group of glycoproteins.
with these amino acids following inulin supplementation. Our 
data therefore indicate that the observed improvement in insulin 
sensitivity following inulin supplementation was related to a 
favourable modulation of amino acid metabolism.
Previous reports have linked raised colonic SCFA production 
with anti-inflammatory responses, thus we explored the effects 
of IPE supplementation on a range of systemic inflammatory 
and immune parameters. Findings from murine models would 
predict that raising colonic propionate delivery would expand 
the proportion of Treg cells, while proinflammatory Th17 cells 
would be lowered,23 26 33 although the majority of effects have 
been limited to colonic immune subsets rather than systemic 
populations. Until the present study, there has been limited 
opportunity to explore these impacts in a human cohort. Both 
inulin and IPE supplementation induced a modest enhancement 
in peripheral Tregs, although this did not reach significance. 
Neither IPE nor inulin supplementation had significant effect 
on T cell effector recall responses to antigens. We found that 
IPE significantly decreased circulating IL-8 levels compared with 
cellulose supplementation. This outcome was supported by our 
observation that propionate significantly reduced the secretion 
of IL-8 from cultured human PBMCs. SCFAs have recently been 
shown to supress IL-8 production from human intestinal Caco-2 
cells34 and human umbilical vein endothelial cells.35 It was 
also shown that propionate had a greater potency to suppress 
IL-8 expression compared with acetate34 and the present study 
observed that the reduction in IL-8 from human PBMCs was only 
found with propionate and not acetate. IL-8 is a key chemokine 
bringing neutrophils and macrophages to sites of inflammation 
and contributing to the proinflammatory profile characteristic of 
metabolic syndrome.21 This chemotaxis can subsequently impact 
processes that impair insulin signalling,21 and studies have asso-
ciated elevated levels of IL-8 with increased insulin resistance 
in humans.36 37 Consequently, the inhibition of IL-8 by IPE 
supplementation appears to be driven by the selective delivery 
of propionate to the colon and may partly explain the observed 
improvements in glucose homeostasis.
IPE supplementation also promoted a small but highly 
significantly increase in serum IgG levels relative to cellulose. 
The physiological relevance of this minor elevation in periph-
eral IgG in humans is unclear, but is consistent with an obser-
vation from rodent studies that SCFA treatment increases the 
expression of genes that enhance antibody production in B cells, 
which improves systemic immune responses.24 To the best of our 
knowledge, this is the first evidence in vivo in humans that selec-
tively increasing colonic propionate delivery increases circulating 
IgG levels and it would be of future interest to determine if this 
effect of IPE on adaptive immunity can decrease susceptibility to 
pathogen exposure.
Metataxonomic analysis of stool samples compared the 
impact of each supplementation period on gut bacterial compo-
sition. The improvements in metabolic markers following inulin 
and IPE supplementation were observed despite decreased 
stool bacterial diversity compared with cellulose. This outcome 
appears counterintuitive given the commonly accepted asso-
ciation in humans between a lower gut bacterial diversity and 
poor health.38 Nevertheless, previous studies have also found 
that dietary supplementation of a single fermentable substrate 
can reduce indices of stool bacterial diversity in humans,39 yet 
improve metabolic responses.40 No changes were found at the 
phylum level and differences at the class and order level were 
only detected between the inulin and cellulose supplementation 
periods. This finding supports the concept that dietary interven-
tion in ‘free-living’ humans has a more selective effect on gut 
bacterial species compared with the extensive shift in gut bacte-
rial populations reported in rodent models.27 41 We observed 
that both IPE and inulin decreased the abundance of selective 
species of Firmicutes (IPE: B. obeum, E. ruminantium; inulin: 
B. obeum, B. luti, B. faecis, R. faecis, Oscillibacter spp) and 
stimulated the growth of Bacteroides spp (IPE: B. uniformis, B. 
xylanisolvens; inulin: B. caccae) compared with cellulose. This 
observation supports our previous work in vitro showing that 
both IPE and inulin increase the abundance of Bacteroides spp.16 
The improvement in metabolic homeostasis following dietary 
supplementation with inulin-type fructans has been linked to an 
increased growth of Bifidobacterium spp,27 42 which have also 
been shown to decrease in obesity and type 2 diabetes.43 44 Inter-
estingly, only inulin supplementation promoted a bifidogenic 
effect, with increased abundance of B. faecale compared with 
both cellulose and IPE. The difference between inulin and IPE 
confirms our observations in vitro16, but was unanticipated 
considering that 20 g/day IPE supplementation would itself 
provide 14.6 g/day of inulin to the diet, and previous work has 
demonstrated that lower intakes (12 g/day) stimulate Bifidobacte-
rium abundance in the human faecal microbiota.41 We conclude 
that the high levels of propionate delivered to the colon by IPE 
inhibit the bifidogenic action of inulin fermentation. Previous 
investigations in both animal and human models have linked the 
increased abundance of bifidobacteria from feeding inulin-type 
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Figure 3 (A) The proportion of CD4+ Treg and (B) Th17 cells, (C) the ratio of Treg:Th17, (D) the proportion of CD19+ B cells, (E) interferon gamma 
(IFNγ) T cell spot forming cell response to the cytomegalovirus/Epstein-Barr virus/flu (CMV/EBV/flu [CEF]) peptide pool, and (F) IFNγ T cell spot forming 
cell response to the Pseudomonas aeruginosa antigen, OprF, following 42 days of cellulose, inulin and inulin-propionate ester (IPE) supplementation. 
Each individual symbol represents a volunteer and lines represent mean±SEM (n=12). (A) and (E) were analysed by repeated measures analysis of 
variance (ANOVA). (B), (C), (D) and (F) were analysed by Friedman test. sfc, spot forming cell. 
fructans with an improved gut barrier function.27 42This change 
has been associated with improvements in host glucose homeo-
stasis through reduced endotoxaemia, which can directly induce 
insulin resistance in peripheral tissues.45 It is therefore surprising 
that the observed changes in gut bacterial populations with 
inulin supplementation were not associated with altered inflam-
matory and immune responses. Inflammatory changes were, 
however, only measured in peripheral blood samples and we 
cannot exclude the possibility that the changes in gut bacterial 
composition promoted by inulin supplementation had local-
ised effects on inflammatory responses within the intestinal 
mucosal environment.46 47 Despite the increase in bifidobacteria 
following inulin supplementation there were no differences in 
circulating LBP following the three supplementation periods. 
The bifidogenic action of inulin fermentation and reduced endo-
toxaemia reported in rodent studies has commonly been found 
in animals fed a high-fat diet, which promotes considerable 
impairments to gut integrity.42 In comparison, all volunteers in 
the present study had relatively low levels of LBP (<15 µg/mL), 
suggesting there was limited scope for the bifidogenic effect of 
inulin to translate into improvements in gut permeability.
We hypothesised that IPE supplementation would reduce 
NEFA levels, as found in our previous experiments,18 yet fasting 
and postprandial NEFA concentrations were unaffected after 
IPE feeding relative to both inulin and cellulose. The major 
methodological differences that may explain this discrepancy 
are the shorter supplementation period in the present study 
and the fact that the IPE was not provided with the standard 
test meal. This methodological detail may also explain why we 
were unable to detect any differences in circulating SCFAs or 
anorectic hormone release between the three supplementation 
periods. Blood samples were collected and analysed following 
an overnight fast and up to 180 min following a standard mixed 
meal test. A longer study protocol (>6 hours) with the addition 
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Figure 4 (A) IgG and (B) IL-8 in fasting serum following 42 days of 
cellulose, inulin and inulin-propionate ester (IPE) supplementation. Each 
individual symbol represents a volunteer and lines represent mean±SEM 
(n=12). (C) IL-8 release from peripheral blood mononuclear cells 
(PBMC) isolated from 12 healthy volunteers cultured for 48 with 4 mM 
sodium chloride, 4 mM sodium acetate and 4 mM sodium propionate. 
The concentration of IL-8 produced following culture with media alone 
was subtracted from the treated samples to determine change in IL-8. 
Mean±SEM (n=12). *P<0.05; **P<0.01. (A) was analysed by repeated 
measures analysis of variance (ANOVA) with post hoc Fisher's least 
significant difference (LSD) tests. (B) and (C) were analysed by Friedman 
test and post hoc Wilcoxon signed-rank test. IL-8, interleukin-8.
of the fermentable substrates to the test meal may have been 
necessary to observe differences in peripheral circulating levels 
of SCFAs and their potential effects on intestinal PYY and GLP-1 
release.48 We chose not to add the fibre supplements to the test 
meal so that any observed effect on postprandial metabolism 
was independent of possible acute alterations in digestion and 
absorption caused by the physiochemical properties of each fibre 
supplement.
In summary, in a cohort of adults with overweight and obesity 
both inulin and IPE supplementation improved measures of 
insulin resistance relative to cellulose, however, there was no 
significant difference between IPE and inulin. Despite this compa-
rable improvement to metabolic health, IPE supplementation 
generated distinct effects on gut bacterial species and markers 
of systemic inflammation and immune function compared with 
those observed with the supplementation of inulin alone. Taken 
together, the present study suggests that manipulating the colonic 
fermentation profile of a dietary fibre in favour of propionate 
promotes selective effects on the mechanisms that contribute 
to metabolic dysregulation. It would be of interest to establish 
the individual effects of delivering acetate and butyrate to the 
colon as, in the future, this would support the development of 
fermentable carbohydrate that delivers a specific SCFA profile to 
improve metabolic health and glucose homeostasis.
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